ArticleScientific reports2026
Age-dependent and reversible refractive changes in 0-6 years old children associated with reduced outdoor activity: a six-year community-based study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Outdoor activity is known to protect against childhood myopia, particularly in school-aged children. However, limited evidence exists regarding how reduced outdoor exposure influences refractive development in younger children, especially those under 3 years old. We conducted a cross-sectional, population-based study of 70,490 children aged 0-6 years in Guangzhou, China, from 2018 to 2023. Annual refractive screenings were performed using a validated non-cycloplegic photoscreener (SW-800 refractive screener, Suoer Electronics, China). Children were stratified by age group and screening year. We analyzed trends in mean spherical equivalent (SE) and premyopia prevalence (SE between - 0.50 and + 0.75 diopters (D)), focusing on the effects of reduced outdoor activity in 2020 . Between 2018 and 2019, the equivalent spherical refractive error (SE) in children across all age groups remained stable, indicating a consistent hyperopic reserve. For the 1-year-old group, the SE was 0.66 ± 1.30 D in 2018 and 0.64 ± 1.19 D in 2019. For the 2-year-old group, the SE was 0.61 ± 1.06 D in 2018 and 0.63 ± 0.95 D in 2019. In the 3-6-year-old group, the mean SE ranged from 0.35 ± 0.83 D to 0.56 ± 0.88 D. During the same period, the prevalence of pre-myopia was between 50.96% and 77.99%. In 2020, during the home confinement period, all age groups showed a significant myopic shift, with the mean SE decreasing by 0.36-0.56 D compared to 2019. Specifically, for the 1-year-old group, the SE was 0.14 ± 0.75 D; for the 2-year-old group, it was 0.07 ± 0.42 D; for the 3-year-old group, it was 0.08 ± 0.50 D; for the 4-year-old group, it was 0.04 ± 0.56 D; for the 5-year-old group, it was 0.08 ± 0.53 D; and for the 6-year-old group, it was - 0.01 ± 0.46 D. The prevalence of pre-myopia reached its peak in all age groups in 2020 (80.26% in the 1-year-old group, and exceeding 94% in the 2-6-year-old groups), showing a significant increase compared to 2018-2019.The risk of pre-myopia in 2018 and 2019 was significantly lower than in 2020 (all OR < 0.30, P < 0.001). This study employed a cross-sectional design, with participants studied by year and age group independently. The trends observed reflect population-level refractive changes rather than individual longitudinal recovery trajectories. Reduced outdoor activity is associated with transient, age-dependent myopic shifts in children aged 0-6 years, particularly among those under 3 years. Findings support early integration of outdoor exposure in paediatric myopia prevention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.